Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Main subject
Language
Publication year range
1.
Cytokines Cell Mol Ther ; 7(1): 15-24, 2002 Mar.
Article in English | MEDLINE | ID: mdl-12171247

ABSTRACT

Dendritic cell (DC) counts and function were assayed in peripheral blood of lymphoma and solid tumor patients before and after chemotherapy. The DC counts declined significantly within the first week from the start of chemotherapy, recovered in the second week, and exceeded the baseline values in the third week. DC recovery was usually similar after the first and after the last cycle of chemotherapy. DC1 and DC2 subsets followed the pattern of reconstitution found for the DC population as a whole. Monocytes and granulocytes recovered 1-2 weeks later than DC. The primary proliferative response to keyhole lympet hemocyanin (KLH), totally DC-dependent, declined within the first week from the start of chemotherapy, and in the majority of patients (including those initially unresponsive) recovered along with DC counts. The recovered responsiveness to KLH, but not to anti-CD3 antibody, disappeared at the end of chemotherapy in lymphoma and some solid tumor patients. Prolonged depletion of CD4+ T cells could contribute to the loss of responsiveness in lymphoma patients receiving multiple cycles of chemotherapy. However, in some solid tumor patients, the reactivity to KLH was absent, despite the reconstitution of both DC and CD4+ T-cell counts. Our data show that numerical reconstitution of DC is not necessarily accompanied by functional recovery. The early recovery of DC should be considered while designing protocols for DC collection for immunotherapy.


Subject(s)
Neoplasms/blood , Neoplasms/drug therapy , Adult , Antibodies, Monoclonal/metabolism , CD3 Complex/biosynthesis , CD4-Positive T-Lymphocytes/metabolism , Cell Division , Dendritic Cells/cytology , Female , Hemocyanins/metabolism , Humans , Immunophenotyping , Immunotherapy/methods , Interleukin-2/metabolism , Lymphoma/blood , Lymphoma/drug therapy , Male , Middle Aged , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...